Trial · NCT00208949
A Comparison of Dendritic Cell Content and T-Cell Phenotype Between Granulocyte Colony-Stimulating Factor (G-CSF) or G-CSF + Granulocyte Macrophage (GM)-CSF
NCT00208949, Phase 2, Terminated, Emory University; results first posted 2012-09-14
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Comparison of Dendritic Cell Content and T-Cell Phenotype Between Granulocyte Colony-Stimulating Factor (G-CSF) or G-CSF + Granulocyte Macrophage (GM)-CSF. Trials, record NCT00208949. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00208949
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Comparison of Dendritic Cell Content and T-Cell Phenotype Between Granulocyte Colony-Stimulating Factor (G-CSF) or G-CSF + Granulocyte Macrophage (GM)-CSF
- NCT number
- NCT00208949
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 50 participants, actual
- Lead sponsor
- Emory University
- Conditions
- Hematologic Diseases
- Interventions
- G-CSF, GM-CSF
- First posted
- 2005-09-21
- Last updated
- 2012-09-14
- Results first posted
- 2012-09-14
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Measure the pDC (Plasmacytoid Dendritic Cells )Content of the Graft | at transplant (1 day) | |
| Secondary | Median Survival of Recipients of Grafts Mobilized With GM+G+CSF (Granulocyte Colony-Stimulating Factor (G-CSF)+ Granulocyte Macrophage (GM)-CSF) and G-CSF (Granulocyte Colony-Stimulating Factor )at the Time of Last Follow up. | 5 years | Median overall survival |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Measure the pDC (Plasmacytoid Dendritic Cells )Content of the Graft | at transplant (1 day) | Sample size determinations for this randomized trial were based on a baseline frequency of mDCs(myeloid dendritic cells) and pDCs( plasmacytoid dendritic cells)within the peripheral blood of 0.5% with a SD equal to the mean (0.5%). | x10 ^ 6 cells/kg | MEDIAN |
| SECONDARY | Median Survival of Recipients of Grafts Mobilized With GM+G+CSF (Granulocyte Colony-Stimulating Factor (G-CSF)+ Granulocyte Macrophage (GM)-CSF) and G-CSF (Granulocyte Colony-Stimulating Factor )at the Time of Last Follow up. | 5 years | months | MEDIAN |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Measure the pDC (Plasmacytoid Dendritic Cells )Content of the Graft | G-CSF (Granulocyte Colony- Stimulating Factor) | 4 | Standard Error 1 | x10 ^ 6 cells/kg | |
| Measure the pDC (Plasmacytoid Dendritic Cells )Content of the Graft | G-CSF and GM-CSF (Granulocyte Macrophage) | 2.5 | Standard Error 1 | x10 ^ 6 cells/kg | |
Median Survival of Recipients of Grafts Mobilized With GM+G+CSF (Granulocyte Colony-Stimulating Factor (G-CSF)+ Granulocyte Macrophage (GM)-CSF) and G-CSF (Granulocyte Colony-Stimulating Factor )at the Time of Last Follow up. | G-CSF (Granulocyte Colony- Stimulating Factor) | 38.3 | Full Range 0 to 60 | months | |
Median Survival of Recipients of Grafts Mobilized With GM+G+CSF (Granulocyte Colony-Stimulating Factor (G-CSF)+ Granulocyte Macrophage (GM)-CSF) and G-CSF (Granulocyte Colony-Stimulating Factor )at the Time of Last Follow up. | G-CSF and GM-CSF (Granulocyte Macrophage) | 7.3 | Full Range 0 to 60 | months |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | G-CSF (Granulocyte Colony- Stimulating Factor) | 25 | |
| Overall Study | STARTED | G-CSF and GM-CSF (Granulocyte Macrophage) | 25 | |
| Overall Study | COMPLETED | G-CSF (Granulocyte Colony- Stimulating Factor) | 25 | |
| Overall Study | COMPLETED | G-CSF and GM-CSF (Granulocyte Macrophage) | 25 | |
| Overall Study | NOT COMPLETED | G-CSF (Granulocyte Colony- Stimulating Factor) | 0 | |
| Overall Study | NOT COMPLETED | G-CSF and GM-CSF (Granulocyte Macrophage) | 0 |
Source ClinicalTrials.gov
Adverse events10
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Fever | General disorders | G-CSF (Granulocyte Colony- Stimulating Factor) | 2 | 25 | |
| other | Fever | General disorders | G-CSF and GM-CSF (Granulocyte Macrophage) | 9 | 25 | |
| other | Bone Pain | Musculoskeletal and connective tissue disorders | G-CSF (Granulocyte Colony- Stimulating Factor) | 12 | 25 | |
| other | Bone Pain | Musculoskeletal and connective tissue disorders | G-CSF and GM-CSF (Granulocyte Macrophage) | 19 | 25 | |
| other | Injection site redness | Skin and subcutaneous tissue disorders | G-CSF (Granulocyte Colony- Stimulating Factor) | 1 | 25 | |
| other | Injection site redness | Skin and subcutaneous tissue disorders | G-CSF and GM-CSF (Granulocyte Macrophage) | 3 | 25 | |
| other | Injected site pain | Musculoskeletal and connective tissue disorders | G-CSF (Granulocyte Colony- Stimulating Factor) | 2 | 25 | |
| other | Injected site pain | Musculoskeletal and connective tissue disorders | G-CSF and GM-CSF (Granulocyte Macrophage) | 5 | 25 | |
| serious | Death | Blood and lymphatic system disorders | G-CSF (Granulocyte Colony- Stimulating Factor) | 7 | 25 | |
| serious | Death | Blood and lymphatic system disorders | G-CSF and GM-CSF (Granulocyte Macrophage) | 7 | 25 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | G-CSF (Granulocyte Colony- Stimulating Factor) | ||
| Total, all-cause mortality | G-CSF and GM-CSF (Granulocyte Macrophage) | ||
| Total, other adverse events | G-CSF (Granulocyte Colony- Stimulating Factor) | 17 | 25 |
| Total, other adverse events | G-CSF and GM-CSF (Granulocyte Macrophage) | 25 | 25 |
| Total, serious adverse events | G-CSF (Granulocyte Colony- Stimulating Factor) | 7 | 25 |
| Total, serious adverse events | G-CSF and GM-CSF (Granulocyte Macrophage) | 7 | 25 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| G-CSF (Granulocyte Colony- Stimulating Factor) vs G-CSF and GM-CSF (Granulocyte Macrophage): serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00208949
GET https://conductscience.org/api/trials/v1/NCT00208949/registered